Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3. Temporal trends in individual serum lipid fractions in ICH patients by APOE allele carrier status Temporal trends in individual serum lipid fractions.

Published byἈσκληπιός Αλεξανδρίδης Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 3. Temporal trends in individual serum lipid fractions in ICH patients by APOE allele carrier status Temporal trends in individual serum lipid fractions."— Presentation transcript:

1 Figure 3. Temporal trends in individual serum lipid fractions in ICH patients by APOE allele carrier status Temporal trends in individual serum lipid fractions in ICH patients by APOE allele carrier status (A–D) Loess smoothed curves of serum lipid levels (mg/dL) against time (in months) before and after ICH. Gray areas indicate standard error (SE). Time period of interest is indicated by shaded boxes (P2 0–6 months pre-ICH). *p < , rate of change of serum lipids by Wald test for time period P2 in APOE ε2 or ε4 carrier status compared with reference (APOE ε3/ε3). ICH = intracerebral hemorrhage. Chia-Ling Phuah et al. Neurol Genet 2016;2:e81 © 2016 American Academy of Neurology

Download ppt "Figure 3. Temporal trends in individual serum lipid fractions in ICH patients by APOE allele carrier status Temporal trends in individual serum lipid fractions."

Similar presentations

Figure Pedigrees of the SCA42 families identified in this study

Figure Pedigrees of the SCA42 families identified in this study
Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)
Figure 2. Infliximab treatment effect

Figure 2. Infliximab treatment effect
Figure 3 Pedigree of familial idiopathic transverse myelitis

Figure 3 Pedigree of familial idiopathic transverse myelitis
Figure 1 Percentages of patients with first seizure experiencing a recurrent seizure over time This graph is based on a fixed-effect pooled percentage.

Figure 1 Percentages of patients with first seizure experiencing a recurrent seizure over time This graph is based on a fixed-effect pooled percentage.
Figure 1 Box plot of the venous diameter in lesions

Figure 1 Box plot of the venous diameter in lesions
Figure 2 Needle biopsy of the left vastus lateralis

Figure 2 Needle biopsy of the left vastus lateralis
Figure 2 Association of serum IgG reactivity with MRI measures of disease severity Association of serum IgG reactivity with MRI measures of disease severity.

Figure 2 Association of serum IgG reactivity with MRI measures of disease severity Association of serum IgG reactivity with MRI measures of disease severity.
Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.
Figure 2 FXTAS Rating Scale scores for case 1

Figure 2 FXTAS Rating Scale scores for case 1
Figure 2. Ophthalmologic findings of bialleic AP5Z1 mutations

Figure 2. Ophthalmologic findings of bialleic AP5Z1 mutations
Figure Pedigree of the family

Figure Pedigree of the family
Figure Increase of publications relating to genetics and neurology Pubmed was searched for the following advanced search term: (gene[Text Word]) OR mutation[Text.

Figure Increase of publications relating to genetics and neurology Pubmed was searched for the following advanced search term: (gene[Text Word]) OR mutation[Text.
Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.
Figure 2. EZO levels in infants and young children compared to adults at similar doses EZO levels in infants and young children compared to adults at similar.

Figure 2. EZO levels in infants and young children compared to adults at similar doses EZO levels in infants and young children compared to adults at similar.
Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)

Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)
Figure 2 Comparison between noncarriers (−) and carriers (+) of the minor allele of rs4388808 (CYP2C19)‏ Comparison between noncarriers (−) and carriers.

Figure 2 Comparison between noncarriers (−) and carriers (+) of the minor allele of rs (CYP2C19)‏ Comparison between noncarriers (−) and carriers.
Figure 1 Dominant and recessive missense and nonsense variants in neurofilament light (NEFL)‏ Dominant and recessive missense and nonsense variants in.

Figure 1 Dominant and recessive missense and nonsense variants in neurofilament light (NEFL)‏ Dominant and recessive missense and nonsense variants in.
Figure 3 Temporal trends in FALS incidence

Figure 3 Temporal trends in FALS incidence
Figure 5 Neurite structure is not disrupted by the lack of neurofilament light (NEFL)‏ Neurite structure is not disrupted by the lack of neurofilament.

Figure 5 Neurite structure is not disrupted by the lack of neurofilament light (NEFL)‏ Neurite structure is not disrupted by the lack of neurofilament.

Similar presentations

Ads by Google